CTOs on the Move

Albireo Pharma

www.albireopharma.com

 
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Joan Connolly
Chief Technology Officer Profile
Tyson Kamikawa
Vice President Information Technology Profile

Similar Companies

CHR Hansen

Chr. Hansen is a leading manufacturer of natural food color, with companies in over thirty countries, and color factories and application centers all over the world. Among the company's clients are some of the market leaders within the food and beverage

Lindus Health

Lindus Health is a next generation CRO that helps biotech and healthtech pioneers run faster, more reliable clinical trials. They provide end-to-end clinical trial services, including trial design, recruitment, and delivery, and have a unique technolog...

bellatrx

bellatrx is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

U.S. Dermatology Partners

We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.

MAPS Public Benefit Corporation

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics.